CDKN2A PROMOTER HYPERMETHYLATION

在许多癌症类型中，CDKN2A的丢失是一个重要事件。这种情况发生的一种机制是CDKN2A启动子区域的高甲基化。虽然没有靶向治疗参与临床试验，但通过一些荟萃分析研究了预后的影响。启动子高甲基化的预后影响相对不明确。许多研究显示，在结直肠癌、肝癌和年轻肺癌患者中，高甲基化患者的预后较差。尽管如此，在这成为一个被广泛接受的预后指标之前，仍有研究要做。
CDKN2A loss has been shown to be a significant event in a number of cancer types. One mechanism by which this can occur is by hypermethylation of the CDKN2A promoter region. While no targeted therapeutic has been engaged in clinical trials, the prognostic impact has been studied by a number of meta-analyses. The prognostic impact of promoter hypermethylation has been relatively ambiguous. Many studies have shown significant p-values suggesting poorer prognostic outcomes for patients with hypermethylation in colorectal, liver, and younger lung cancer patients. This being said, there is still research to be done before this becomes a widely-accepted prognostic indicator.